ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Engineering DNA Origami Captors for TGFβ1 Sequestration to Enhance Tumor Immune Modulation and Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Blueprint to Breakthrough: How Far Can We Fold DNA Origami for Nano-Enabled Technologies?JACS Au · 2026Review
- Review
- Engineering DNA Origami Captors for TGFβ1 Sequestration to Enhance Tumor Immune Modulation and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Efficient modulation of pivotal immune-regulatory molecules to leverage the tumor microenvironment (TME) and enhance therapeutic effects remains an ideal yet challenging goal. TGFβ1 represents a critical therapeutic target as a key cytokine involved in immune suppression and tumor progression. Here, a DNA origami-based framework functionalized with anti-TGFβ1 aptamers is developed to act as a captor for efficient TGFβ1 sequestration and fast clearance, thereby improving anti-tumor immunity. By engineering the geometric shapes and pore sizes of three DNA framework captors (DFCs), the superior efficacy of a barrel-shaped captor (DBC) in regulating TGFβ1 levels is demonstrated. In cell culture, DBCs significantly enhance T cell-mediated tumor cytotoxicity, while systemic administration effectively inhibits tumor growth in the mouse model. Moreover, DBCs demonstrate a synergistic effect with PD-L1 antibody to enhance anti-tumor efficacy. Immunohistochemistry (IHC) further confirmes the DBC-mediated reduction of TGFβ in tumor tissue and its biodistribution fate. These findings underscore the importance of cytokine regulation in cancer immunotherapy and provide valuable insights for the rational design and application of structural DNA nano-devices as a transformative tool for precise immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.